[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transplantfailurekidney\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transplantfailurekidney":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,83,112,144,168,198],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100486356","leveraging-technology-to-improve-medication-adherence-in-youth-with-kidney-or-liver-transplant-100486356",false,"NCT05613010","Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant","Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients: A Micro-Randomized Trial","Inclusion Criteria:\n\n* Adolescents and young adults (13-25 years old) who underwent kidney or liver transplantation at least 6 months prior to enrollment\n* Currently prescribed tacrolimus or sirolimus.\n\nExclusion Criteria:\n\n* Currently receiving dialysis\n* Hospitalized for duration of study\n* Significant developmental or cognitive delay\n* No access to a mobile device that supports text messaging\n* Decline to use electronic pill box to monitor daily medication adherence\n* Non-English speaking\n* If a participant meets inclusion criteria, enrolls in the study, and experiences graft failure potentially leading to dialysis in the case of kidney transplant recipients, the participant will be given the option to continue in the study if they remain on tacrolimus or sirolimus.","ALL","13 Years","25 Years",{"count":20,"type":21},65,"ESTIMATED","INTERVENTIONAL",[24],"NA","Can the investigators create an effective way to improve adherence to immunosuppressant medication and reduce rejection, graft loss, and death in adolescents and young adults who have undergone kidney or liver transplantation? The investigators' mobile technology intervention uses real-time electronic pillbox-assessed dose timing and text message prompts to address antirejection medication nonadherence when nonadherence is detected.",[27,28,29,30,31],"Transplant;Failure,Kidney","Transplant; Failure, Liver","Adherence, Medication","Adherence, Patient","Adherence, Treatment",[33,34,35,36,37,38,39,40],"kidney transplant","liver transplant","medication adherence","medication nonadherence","compliance","mobile health","mobile phone","technology","RECRUITING","2026-04-09",{"date":44,"type":45},"2026-04-13","ACTUAL",{"date":47,"type":45},"2024-03-19",{"date":49,"type":21},"2026-11-30",{"name":51,"class":52},"Johns Hopkins University","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":53},"100342360","phase-4-tap-blocks-with-ropivacaine-continuous-infusion-catheters-vs-single-dose-liposomal-bupivicaine-after-kidney-transplant-100342360","NCT03737604","TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant","Transversus Abdominis Plane (TAP) Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine: A Prospective Randomized Control Trial for Pain Control After Renal Transplant Surgery","Inclusion Criteria:\n\n* Patients ages 18 years or older\n* Renal Transplant Recipients\n\nExclusion Criteria:\n\n* Patients less than 18 years of age\n* Pregnant Women\n* Prisoners\n* Opioid Tolerant Patients taking more than 30 mg\u002Fday of oral morphine equivalent analgesia\n* Patients on Systemic anti coagulation\n* Patients unable to provide consent\n* Hypersensitivity to amide-type local anesthetic or any component of the drug formula",true,"18 Years",{"count":64,"type":21},200,[66],"PHASE4","This study is a comparison of the analgesic efficacy of transversus abdominis plane (TAP) blocks with ropivacaine bolus plus continuous ropivacaine infusion via catheters versus single shot TAP blocks with liposomal bupivacaine.",[27,69],"Pain, Postoperative",[71,72,73],"Transversus Abdominis Plane Block","Ropivacaine","Liposomal bupivacaine","2026-02-13",{"date":76,"type":45},"2026-02-18",{"date":78,"type":45},"2018-10-04",{"date":80,"type":21},"2026-06-12",{"name":82,"class":52},"University of California, Davis",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":53},"100345533","enhancing-renal-graft-function-during-donor-anesthesia-100345533","NCT03778944","Enhancing Renal Graft Function During Donor Anesthesia","Renal Graft Functional Enhancement During Donor Anesthesia: A Comparative Study of 3 Modalities","Inclusion Criteria:\n\n* end-stage renal disease, for living-donor kidney transplantation\n\nExclusion Criteria:\n\n* severe cardiac or hepatic dysfunction\n* coagulopathy","60 Years",{"count":92,"type":21},60,[24],"Renal transplantation is now recognized as the treatment of choice for patients with end-stage renal disease. An optimum anesthetic regimen should enhance the function and perfusion of the transplanted kidney. The aim of this study is to assess \\& compare the effectiveness of 3 different modalities in this respect: Mannitol, Dopamine and adequate hydration.",[96,27,97],"Renal Failure Chronic","Anesthesia",[99,100,101,102,97],"Mannitol","Dopamine","Perfusion","Renal graft donor","2026-01-08",{"date":105,"type":45},"2026-01-12",{"date":107,"type":45},"2018-12-20",{"date":109,"type":21},"2026-12",{"name":111,"class":52},"Nazmy Edward Seif",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":130,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":53},"100309634","abdominal-wall-transplant-100309634","NCT03310905","Abdominal Wall Transplant","Abdominal Wall Transplantation for the Reconstruction of Abdominal Wall Defects as Adjunct to Abdominal Solid Organ Transplantation","Inclusion Criteria:\n\n* Candidates between 18-65 years old\n* Willingness and legal ability to give consent\n* Abdominal Wall in combination with another organ transplant: they must be eligible for the non-vascularized composite allograft organ transplant at Duke\n\nExclusion Criteria:\n\n* Malignancy at evaluation or history of malignancy that precludes transplantation\n* Pregnancy: Women who are of childbearing potential must have a negative serum pregnancy test within 48 hours of transplant and agree to use reliable contraception with two contraceptive methods for a minimum of 2 years following abdominal wall transplantation. Subjects seeking to become pregnant following 2 years will be made aware during the consent process that the effect of pregnancy on the transplanted abdominal wall and vice versa is unknown.\n* Medical exclusion criteria for general anesthesia\n* Ongoing substance abuse or history of untreated substance abuse","65 Years",{"count":121,"type":21},5,[24],"The purpose of this protocol is to determine the safety and efficacy of abdominal wall transplantation as a treatment for the reconstruction of abdominal wall defects. Abdominal wall transplantation may be performed alone or in combination with another transplant.",[27,28,125,126,127,128,129],"Transplant; Failure, Bowel","Abdominal Wall Defect","Abdominal Wall Fistula","Abdominal Wall Hernia","Abdominal Wall Injury",[131,132,133,134],"Research","Transplant","Abdominal Wall","Hernia","2026-01-05",{"date":137,"type":45},"2026-01-07",{"date":139,"type":45},"2018-05-01",{"date":141,"type":21},"2028-06-01",{"name":143,"class":52},"Duke University",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100522965","virtual-home-based-physical-pre-habilitation-in-kidney-transplant-candidates-100522965","NCT06089473","Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates","Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates: a Pilot RCT","Inclusion Criteria:\n\n* consecutive individuals with end stage kidney disease (ESKD) (aged ≥18 years), classified as pre-frail (1-2 points), frail (3-4 points) or very frail (5 points) on the Fried's frailty phenotype and who are accepted or in the process of being accepted to enter in the deceased or living donor KT waiting list of the McGill University Health Centre (MUHC), Centre Hospitalier de l'Université de Montreal (CHUM) or University of Alberta Hospital (UAH) for first-time transplantation or re-transplantation\n* English or French speakers\n* is technologically capable of connecting (either independently or through household members\u002Fnext-of-kin) with an online videoconferencing platform through an e-mail invitation (Patients who do not have access to internet will borrow a tablet with internet for the period of the study)\n\nExclusion Criteria:\n\n* Individuals who:\n* are classified as robust (0 points) on their Fried's frailty phenotype score\n* are participating in a structured exercise program (hospital-based or home-based or another trial)\n* are waiting for kidney-pancreas or kidney-liver transplant as those have much longer waiting time\n* are hospitalized for any reason during the assessment for eligibility\n* have a cPRA (calculated panel reactive antibodies) \\>95% and are on the highly sensitized exchange program and expected to have a prolonged waiting times on the waiting list\n* are expected to have a transplant before the end of the 12 week-intervention (e.g. individuals who will receive an organ from a living donor or are type A blood\n* have pre-existing or newly identified significant cognitive impairment\n* have pre-existing or newly identified cardiac, musculoskeletal, neuropathy or neurological condition that might affect their exercise performance or otherwise render rehabilitation participation unsafe",{"count":152,"type":21},30,[24],"The goal of this RCT is to address the feasibility of conducting a 12-week virtual pre-habilitation intervention, which includes exercise and education, in kidney transplant candidates. The intervention also includes a 5-month maintenance phase with independent home exercises (maximum of 8 months of intervention\u002Fended early if the participant undergoes a kidney transplant). The main questions it aims to answer are:\n\n* estimate the proportion of screened patients who meet eligibility criteria\n* estimate the proportion of eligible patients who consent to randomization\n* estimate the proportion of patients who adhere to the interventions\n* estimate follow-up completion rates\n* inform the calculation of sample size requirements for a full-scale RCT\n* assess the acceptability of the intervention by the participants.\n\nParticipants in the control group will receive usual outpatient care.",[156,157,27],"Kidney Disease, End-Stage","Frailty","2025-11-25",{"date":160,"type":45},"2025-12-03",{"date":162,"type":45},"2024-11-02",{"date":164,"type":21},"2027-02",{"name":166,"class":52},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",2,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":53},"100574607","non-invasive-monitoring-of-pediatric-kidney-transplant-recipients-and-immunosuppression-personalization-an-open-labeled-multicenter-randomized-controlled-study-100574607","NCT06761482","Non-Invasive Monitoring of Pediatric Kidney Transplant Recipients and Immunosuppression Personalization: an Open-labeled Multicenter Randomized Controlled Study","MONITOR","Inclusion Criteria:\n\n* Age less than 21 years old at transplantation\n* Single renal transplant from a deceased or a living donor.\n* Absence of pregnancy confirmed by a negative pregnancy test in women in child-bearing period.\n* Subject and legal guardians are willing and able to provide signed written informed consent and to comply with the study procedures\n* Patients affiliated to health insurance system including Aide Médicale de l'Etat (AME)\n\nExclusion Criteria:\n\n* History of multi-organ transplant (interference with rejection natural history)\n* No surveillance biopsy planned\n* Adult patient (or legal guardians) with limited understanding of the French language preventing him from receiving informed information on the protocol","1 Year","21 Years",{"count":178,"type":21},160,[24],"Currently, the monitoring of children receiving a kidney transplantation includes surveillance biopsies to detect subclinical rejection and signs of toxicity of immunosuppressive drugs (tacrolimus).\n\nThe hypothesis of the study is that the combination of non-invasive biomarkers (Donor-derived cell-free DNA and Virus-specific T cells) will allow both the safe discontinuation of surveillance biopsies and the personalization of the exposure to calcineurin inhibitors among pediatric kidney transplant recipients.",[182,27],"Pediatric Kidney Disease",[184,185,186,187],"kidney","transplant","pediatric","rejection","NOT_YET_RECRUITING","2024-12-30",{"date":191,"type":45},"2025-01-07",{"date":193,"type":21},"2025-03-01",{"date":195,"type":21},"2029-03-01",{"name":197,"class":52},"Assistance Publique - Hôpitaux de Paris",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":205,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":53},"100546573","ease-sot-pilot-study-100546573","NCT06396702","EASE-SOT Pilot Study","Emotion And Symptom-focused Engagement (EASE) Intervention for the Management of Emotional and Physical Symptoms Among Solid Organ Transplant Recipients-pilot Study","Inclusion Criteria:\n\n* Participants consented pre-transplant: Potential transplant recipients who are listed on the waitlist and are identified by pre-transplant staff, recipients who have a living donor arranged (pertaining to kidney and liver recipients), participants currently completely pre-transplant prehabilitation (pertaining to lung and heart recipients), or those who are on the top of their respective organ transplant waitlists.\n* Participants consented post-transplant: Incident kidney, kidney-pancreas, liver, lung, or heart transplant recipients identified during index transplant hospital admission at the inpatient transplant unit of the Ajmera Transplant Centre at Toronto General Hospital\n\nExclusion Criteria:\n\n* Patients in ICU.\n* Patients who are clinically unstable, have delirium or other severe mental health concern requiring psychiatric treatment - assessed by clinical team.\n* Non-English speaking patients.\n* Severe cognitive impairment as assessed by the recruitment and\u002For research team. This will be determined through communication with the organ transplant teams and by checking the patient's medical charts. If no cognitive impairment is indicated by the patients organ transplant team or is documented in their medical chart, the patient will be assessed to have no cognitive impairment.\n* Unwilling or unable to provide informed consent.","19 Years",{"count":207,"type":21},120,[24],"Many transplant recipients may experience physical and emotional symptoms, such as anxiety, fatigue, sleep problems, pain, etc. Often, these symptoms are not reported or managed well, and can affect a patient's quality-of-life. Transplant recipients are grateful for the \"gift of life\" but physical and emotional symptoms reduce their quality-of-life. Transplant recipients and caregivers have felt unprepared for the ongoing symptoms and reduced quality-of-life post-transplant.\n\nOne way of monitoring and managing these symptoms is using the Emotion And Symptom-focused Engagement (EASE) intervention. EASE was originally developed for patients with acute leukemia and has begun to be adapted to help monitor and manage physical and emotional symptoms for organ transplant recipients.\n\nEASE is comprised of two components:\n\n1. Psychological - 8 supportive counselling sessions delivered by mental health clinicians to address concerns about mental health, losses from organ failure, coping with a transplant, experiences with living on the brink of death for a prolonged period of time, etc.\n2. Physical - Regular assessments of physical symptoms using questionnaires and referral to healthcare professionals for symptom management as necessary.\n\nEASE uses questionnaires, also called patient reported outcome measures (PROMs), for symptom assessment and monitoring. PROMs measure symptom severity, similarly to how bloodwork measures organ functioning. PROMs, as part of EASE, will ask recipients questions and help identify relevant physical, emotional, and social symptoms to enhance their care.\n\nWith the help of specialists, patients, and support from the Kidney Foundation of Canada, our team has begun to adapt the EASE intervention for transplant recipients. In order to finalize the adaptation of the EASE intervention for use in a routine transplant clinic, we are launching a pre-pilot study to gain real-life experience from managing symptoms of SOT recipients with the use of EASE-SOT.",[27,211,28,212,213],"Transplant; Failure, Heart","Transplant; Failure, Pancreas","Transplant; Failure, Lung(S)","2024-04-29",{"date":216,"type":45},"2024-05-02",{"date":218,"type":21},"2024-05",{"date":220,"type":21},"2027-08",{"name":222,"class":52},"University Health Network, Toronto"]